Key references: Nonhormonal therapy for urinary symptoms in menopause
Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96(3):351–8. https://www.ncbi.nlm.nih.gov/pubmed/10960625
Ferrante KL, Wasenda EJ, Jung CE, Adams-Piper ER, Lukacz ES. Vaginal estrogen for the prevention of recurrent urinary tract infection in postmenopausal women: a randomized clinical trial. Female Pelvic Med Reconstr Surg 2019. https://www.ncbi.nlm.nih.gov/pubmed/31232721
Goldstein I, Dicks B, Kim NN, Hartzell R. Multidisciplinary overview of vaginal atrophy and associated genitourinary symptoms in postmenopausal women. Sex Med 2013;1(2):44–53. https://www.ncbi.nlm.nih.gov/pubmed/25356287
Melville JL, Katon W, Delaney K, Newton K. Urinary incontinence in US women: a population-based study. Arch Intern Med 2005;165(5):537–42. https://www.ncbi.nlm.nih.gov/pubmed/15767530
Sharaf A, Hashim H. Profile of mirabegron in the treatment of overactive bladder: place in therapy. Drug Des Devel Ther 2017;11:463–7. https://www.ncbi.nlm.nih.gov/pubmed/28255232
Shaw C, Gupta RD, Bushnell DM, Assassa RP, Abrams P, Wagg A, et al. The extent and severity of urinary incontinence amongst women in UK GP waiting rooms. Fam Pract 2006;23(5):497–506. https://www.ncbi.nlm.nih.gov/pubmed/16840498
Tse V, King J, Dowling C, English S, Gray K, Millard R, et al. Conjoint Urological Society of Australia and New Zealand (USANZ) and Urogynaecological Society of Australasia (UGSA) Guidelines on the management of adult non-neurogenic overactive bladder. BJU Int 2016;117(1):34–47. https://www.ncbi.nlm.nih.gov/pubmed/26456313
Weber MA, Lim V, Oryszczyn J, Te West N, Souget J, Jeffery S, et al. The effect of vaginal oestriol cream on subjective and objective symptoms of stress urinary incontinence and vaginal atrophy: an international multi-centre pilot study. Gynecol Obstet Invest 2017;82(1):15–21. https://www.ncbi.nlm.nih.gov/pubmed/26990867
